Summary
This multicenter, randomized, blinded, controlled, trial investigated the efficacy and safety of levetiracetam compared with phenobarbital as a preferred treatment for neonatal seizures of any cause. The primary outcome variable was complete seizure freedom for 24 hours, assessed by independent review of the EEGs by 2 experts. Eighty percent of patients randomly assigned to phenobarbital remained seizure free for 24 hours, compared with 28% of patients randomly assigned to levetiracetam (P, .001; relative risk 0.35 [95% confidence interval: 0.22–0.56]; modified intention-to-treat population). A 7.5% improvement in efficacy was achieved with a dose escalation of levetiracetam from 40 to 60 mg/kg. More adverse effects were seen in subjects randomly assigned to phenobarbital (not statistically significant). The authors concluded that phenobarbital was more effective than levetiracetam for the treatment of neonatal seizures and higher rates of adverse effects were seen with phenobarbital treatment.
Similar content being viewed by others
References
Sharpe C, Reiner GE, Davis SL, Nespeca M, Gold JJ, Rasmussen M, et al. Levetiracetam versus phenobarbital for neonatal seizures: a randomized controlled trial. Pediatrics. 2020;145:e20193182.
Kapur J, Elm J, Chamberlain JM, Barsan W, Cloyd J, Lowenstein D, et al. Randomized trial of three anticonvulsant medications for status epilepticus. N Engl J Med. 2019;381:2103–13.
Gowda VK, Romana A, Shivanna NH, Benakappa N, Benakappa A. Levetiracetam versus phenobarbitone in neonatal seizures — a randomized controlled trial. Indian Pediatr. 2019;56:643–6.
McHugh DC, Lancaster S, Manganas LN. A systematic review of the efficacy of levetiracetam in neonatal seizures. Neuropediatrics. 2018;49:12–17.
Sharpe C, Reiner GE, Davis SL, Nespeca M, Gold JJ, Rasmussen M, et al. Levetiracetam versus phenobarbital for neonatal seizures: a randomized controlled trial. Pediatrics. 2020;145:e20193182
Ziobro J, Shellhaas RA. Neonatal seizures: diagnosis, etiologies, and management. Semin Neurol. 2020;40:246–56.
Forcelli PA, Kim J, Kondratyev A, Gale K. Pattern of antiepileptic drug-induced cell death in limbic regions of the neonatal rat brain. Epilepsia. 2011;52:e207–e211.
Forcelli PA, Janssen MJ, Vicini S, Gale K. Neonatal exposure to antiepileptic drugs disrupts striatal synaptic development. Ann Neurol. 2012;72:363–72.
Rao LM, Hussain SA, Zaki T, et al. A comparison of levetiracetam and phenobarbital for the treatment of neonatal seizures associated with hypoxic-ischemic encephalopathy. Epilepsy Behav. 2018;88:212–17.
Kim J, Kondratyev A, Gale K. Antiepileptic drug-induced neuronal cell death in the immature brain: effects of carbamazepine, topiramate, and levetiracetam as monotherapy versus polytherapy. J Pharmacol Exp Ther. 2007;323:165–73.
Sharpe C, Reiner GE, Davis SL, et al. Levetiracetam versus phenobarbital for neonatal seizures: A randomized controlled trial. Pediatrics. 2020;145:e20193182.
Depositario-Cabacar DT, Peters JM, Pong AW, Roth J, Rotenberg A, Riviello Jr JJ, et al. High-dose intravenous levetiracetam for acute seizure exacerbation in children with intractable epilepsy. Epilepsia. 2010;51:1319–22.
Author information
Authors and Affiliations
Corresponding authors
Additional information
Funding
None
Competing interests
None stated
Rights and permissions
About this article
Cite this article
Mathew, J.L., Suthar, R. & Kumar, A. Randomized Controlled Trial Evaluating Levetiracetam as First-line Therapy for Seizures in Neonates. Indian Pediatr 57, 848–853 (2020). https://doi.org/10.1007/s13312-020-1965-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13312-020-1965-9